DUALITYBIO-B (09606) Announces Up to $40 Million Share Buyback, Founder Plans Additional $5 Million Purchase

Stock News05-19

DUALITYBIO-B (09606) announced that its Board of Directors intends to utilize the general mandate granted by shareholders at the Annual General Meeting held on June 20, 2025, to repurchase the company's shares on the open market at appropriate times. The share repurchase program plans to utilize up to US$40 million for share buybacks. The company will fund the repurchases using its internal resources and intends to hold the shares bought back under the program as treasury stock. The Board believes the current trading price of the shares does not reflect their intrinsic value and the company's business prospects, presenting a favorable opportunity for the company to repurchase shares. The share repurchase program reflects the Board and management team's confidence in the company's long-term strategy and growth. The Board considers the share repurchase program to be in the overall best interests of the company and its shareholders. Additionally, based on confidence in the future development prospects of the group and recognition of the company's long-term investment value, Dr. Zhu Zhongyuan, the company's founder, Chairman of the Board, Executive Director, and Chief Executive Officer, intends to use personal funds to purchase additional company shares on the open market, with a total amount not exceeding US$5 million, in compliance with listing rules and other applicable laws and regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112436808?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112436808","market":"fut","top_or_hot":-1,"title":"DUALITYBIO-B (09606) Announces Up to $40 Million Share Buyback, Founder Plans Additional $5 Million Purchase","media":"Stock News","content":"<p>DUALITYBIO-B (09606) announced that its Board of Directors intends to utilize the general mandate granted by shareholders at the Annual General Meeting held on June 20, 2025, to repurchase the company's shares on the open market at appropriate times. The share repurchase program plans to utilize up to US$40 million for share buybacks. The company will fund the repurchases using its internal resources and intends to hold the shares bought back under the program as treasury stock. The Board believes the current trading price of the shares does not reflect their intrinsic value and the company's business prospects, presenting a favorable opportunity for the company to repurchase shares. The share repurchase program reflects the Board and management team's confidence in the company's long-term strategy and growth. The Board considers the share repurchase program to be in the overall best interests of the company and its shareholders. Additionally, based on confidence in the future development prospects of the group and recognition of the company's long-term investment value, Dr. Zhu Zhongyuan, the company's founder, Chairman of the Board, Executive Director, and Chief Executive Officer, intends to use personal funds to purchase additional company shares on the open market, with a total amount not exceeding US$5 million, in compliance with listing rules and other applicable laws and regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DUALITYBIO-B (09606) Announces Up to $40 Million Share Buyback, Founder Plans Additional $5 Million Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDUALITYBIO-B (09606) Announces Up to $40 Million Share Buyback, Founder Plans Additional $5 Million Purchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-19 22:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DUALITYBIO-B (09606) announced that its Board of Directors intends to utilize the general mandate granted by shareholders at the Annual General Meeting held on June 20, 2025, to repurchase the company's shares on the open market at appropriate times. The share repurchase program plans to utilize up to US$40 million for share buybacks. The company will fund the repurchases using its internal resources and intends to hold the shares bought back under the program as treasury stock. The Board believes the current trading price of the shares does not reflect their intrinsic value and the company's business prospects, presenting a favorable opportunity for the company to repurchase shares. The share repurchase program reflects the Board and management team's confidence in the company's long-term strategy and growth. The Board considers the share repurchase program to be in the overall best interests of the company and its shareholders. Additionally, based on confidence in the future development prospects of the group and recognition of the company's long-term investment value, Dr. Zhu Zhongyuan, the company's founder, Chairman of the Board, Executive Director, and Chief Executive Officer, intends to use personal funds to purchase additional company shares on the open market, with a total amount not exceeding US$5 million, in compliance with listing rules and other applicable laws and regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000500386.USD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","start_time":0,"source_url":"","article_id":"1112436808","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112436808","pubTimestamp":1779200266,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"DUALITYBIO-B (09606) announced that its Board of Directors intends to utilize the general mandate granted by shareholders at the Annual General Meeting held on June 20, 2025, to repurchase the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK1161":"生物科技","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","09606":"映恩生物-B"},"translate_title":"DUALITYBIO-B(09606)宣布回购至多4000万美元股票创始人计划追加500万美元购买","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"DUALITYBIO-B (09606) announced that its Board of Directors intends to utilize the general mandate granted by shareholders at the Annual General Meeting held on June 20, 2025, to repurchase the company's shares on the open market at appropriate times. The share repurchase program plans to utilize up to US$40 million for share buybacks. The company will fund the repurchases using its internal resources and intends to hold the shares bought back under the program as treasury stock. The Board believes the current trading price of the shares does not reflect their intrinsic value and the company's business prospects, presenting a favorable opportunity for the company to repurchase shares. The share repurchase program reflects the Board and management team's confidence in the company's long-term strategy and growth. The Board considers the share repurchase program to be in the overall best interests of the company and its shareholders. Additionally, based on confidence in the future development prospects of the group and recognition of the company's long-term investment value, Dr. Zhu Zhongyuan, the company's founder, Chairman of the Board, Executive Director, and Chief Executive Officer, intends to use personal funds to purchase additional company shares on the open market, with a total amount not exceeding US$5 million, in compliance with listing rules and other applicable laws and regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112436808","isCrawlerRequest":true}